Huibin Lv1, Shilei Zhao1, Jinguang Wang1 and Liu Yin2*
1Department of Thoracic Surgery, The First Affiliated Hospital of Dalian Medical University, China
2Department of Oncology, The First Affiliated Hospital of Dalian Medical University, China
Osimertinib, a third-generation Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors (EGFR-TKIs), is the second-line treatment of choice for lung cancer patients who develop T790M mutation resistance after treatment with EGFR-TKIs, but resistance still inevitably occurs after use, and the mechanism of resistance and the choice of treatment regimen after resistance remain unclear. We report a case of right lung adenocarcinoma with intrapulmonary Metastasis (pT2N0M1b, stage IV) that developed T790M/trans-C797S-EGFR-mutate after and to provide clinical evidence of EGFR-TKIs in the treatment of lung cancer and to provide reference for future studies on the treatment of similar cases and the mechanism of resistance to Osimertinib.
Lv H, Zhao S, Wang J, Yin L. Combination of Amineptine and Gefitinib Overcome Acquired Resistance in T790M/trans-C797SEGFR- Mutated Non-Small Cell Lung Cancer: A Case Report. Clin Surg. 2022; 7: 3585..